Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease
Rivaroxaban Monotherapy vs Combination Therapy With Antiplatelets on Total Thrombotic and Bleeding Events in Atrial Fibrillation With Stable Coronary Artery Disease
复制标题
利伐沙班单药治疗与抗血小板联合治疗对稳定型冠状动脉疾病房颤患者总血栓形成和出血事件的影响
DOI：
10.1001/jamacardio.2022.1561
复制
发表时间：
2022
期刊：
影响因子：
24
通讯作者：
e
中科院分区：
文献类型：
--
作者：
Naito Ryo;Miyauchi Katsumi;Yasuda Satoshi;ichishita Ichiro;Fujikura Hisanori;Momomura Shinichi;uichi;Kagiyama Shuntaro;Teragawa Hiroki;Yuge Masaru;ihiko;Horiuchi Masataka;Nagano Toshihiko;Takaishi Atsushi;Nakamura Yuichi;Komaru Tatsuya;Hosokawa Takeshi;e
本文讨论了评估利伐沙班单药治疗冠状动脉疾病患者心房颤动与抗血小板药物联合治疗预防血栓和出血事件的疗效的研究。该研究测量了接受单一疗法和联合疗法的患者的总死亡率和出血频率。它表明单一疗法在降低心血管和出血事件风险方面优于联合疗法。
The article discusses research which evaluated the efficacy of rivaroxaban monotherapy for atrial fibrillation in coronary artery disease patients compared to combination therapy with antiplatelet drugs for preventing thrombotic and bleeding events. The study measured total mortality and frequency of bleeding among patients on monotherapy and combination therapy. It suggests the superiority of monotherapy over combination therapy in lowering the risk of cardiovascular and bleeding events.